IL

Ind-Swift Laboratories Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Ind-Swift Laboratories Q2 Results 2026: PAT ₹34 Cr (+325% YoY)

Q2 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹240Cr
+50.9% YoY
+25.7% QoQ
Net profit
₹34Cr
+325% YoY
+36% QoQ
Margin
19%
+14.3 pp YoY
+2 pp QoQ

What the Q2 FY27 call signalled

4 of 4 strong

RevenueStrong growth
MarginMargins up
CapexCapex planned
Order bookOrder book rising
Price₹349
Market cap₹3.0K Cr
P/E33.1

The short version

FY27: Ind-Swift reiterates guidance of over 50% revenue growth, with H1 FY27 revenue at ₹421 crore (up 35.79% YoY) and confident of meeting full-year targets. Ind-Swift Laboratories expects over 50% revenue growth in FY27, with comfortable achievement of guidance based on H1 performance.

From Ind-Swift Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 10 Nov 2026.

How did Ind-Swift Laboratories' revenue grow in the September 2026 quarter?

Strong growth
  • FY27: Ind-Swift reiterates guidance of over 50% revenue growth, with H1 FY27 revenue at ₹421 crore (up 35.79% YoY) and confident of meeting full-year targets.
  • FY28-29: Growth driven by ramp-up of existing pipeline and approved molecules; new R&D molecules expected to start registrations in early FY28 and commercialization by late FY28/FY29.
  • FY28: CDMO revenues (currently ₹65 crore in H1 FY27) anticipated to grow with increased run-rate; contract manufacturing to comprise ~35% of export revenues, own brands ~65%.
  • FY30: Target to cross ₹1,500 crore revenues with 20-25% CAGR over medium term and 200-300 bps EBITDA margin expansion.

2 more points from Ind-Swift Laboratories Ltd's call on revenue

Create a free account to keep reading this call

What happened to Ind-Swift Laboratories' margins in Q2 FY27?

See what Ind-Swift Laboratories Ltd said on profitability & margins — free account, 30 seconds.

What capex is Ind-Swift Laboratories planning?

Capex planned
  • Ongoing ₹250 crore growth capex covering:
  • Samba facility EU-GMP and PIC/S upgrade (₹45 crore)
  • Derabassi warehouse development adjacent to 100% EOU facility
  • New R&D infrastructure development
  • Capacity debottlenecking at manufacturing sites
  • Construction started on Derabassi warehouse, expected completion in 10-12 months
  • Samba facility upgrades aimed at unlocking regulated market access for topical and oral formulations, with ANVISA visit expected last quarter and PIC/S approval anticipated next year

2 more points from Ind-Swift Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Ind-Swift Laboratories raising money or cutting debt?

See what Ind-Swift Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Ind-Swift Laboratories' order book?

Order book rising
  • Orders are currently in hand as per Gagan Aggarwal's statement in Q2 FY27 call (Page 14).
  • Raw materials are lined up, and manufacturing facilities are equipped, indicating preparedness to fulfill orders.
  • Ongoing discussions with two other customers beyond Viatris and Aerotex are in advanced stages, with hopes to conclude deals in the last quarter (Page 12).

2 more points from Ind-Swift Laboratories Ltd's call on order book

Create a free account to keep reading this call

Ind-Swift Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Ind-Swift Laboratories Ltd Q2 FY27 results — key figures

Ind-Swift Laboratories Ltd Q2 FY27 reported results vs Q2 FY26, ₹ crore
₹ CrQ2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue240159+50.9%191+25.7%
Operating profit (EBITDA)457+542.9%33+36.4%
Operating margin19%4.7%+14.3 pp17%+2 pp
Profit before tax4310+330%33+30.3%
Net profit (PAT)348+325%25+36%
EPS (₹)3.940.98+302%2.84+38.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹34 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

What Ind-Swift Laboratories's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Ind-Swift Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Ind-Swift Laboratories Ltd Q2 FY27 results?

Ind-Swift Laboratories reported net profit of ₹34 Cr (+325% YoY) on revenue of ₹240 Cr (+50.9% YoY) in Q2 FY27.

What is Ind-Swift Laboratories Ltd share price analysis?

Ind-Swift Laboratories Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 33.1 with a market cap of ₹3,041 Cr. Investors should review the full earnings analysis for detailed insights.

Is Ind-Swift Laboratories Ltd planning capital expenditure?

Ongoing ₹250 crore growth capex covering:.

Keep Ind-Swift Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.